Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-70
SponsorNicolai Jacob Wewer Albrechtsen

About this trial

The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied.

The golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism.

We will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate.

Healthy participants will be included, and each participant will participate in one study day, which includes intravenous administration of radioactively labelled glucose (18-FDG), arterial blood sampling and PET scans.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Capable of understanding the participant information and signing the consent form

Between 25 and 70 years of age

Body mass index <= 25 kg/m²

Disqualifiers

Enrolment in other research project that might interfere with the study

Diabetes diagnosis

Pregnancy or breastfeeding

Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol

Trial design

Design model

Single group

Treatments tested in this trial

  • PET with 18-FDG

    Other intervention

    The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.

Treatment groups

6 Participants
are divided into 1 treatment group
Group A: PET with 18-FDGExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Tmax correlation

Difference between the blood-brain glucose transfer capacity (Tmax) calculated based on the image derived input function and Tmax calculated based on the arterial input funcion.

Time frame
From administration of 180MBq 18-FDG and during the approximately first 15 min of the brain PET scan

Secondary outcomes

1

CMRglc correlation

Difference between cerebral metabolic rate of glucose (CMRglc) calculated based on the image derived input function and CMRglc calculated based on the arterial input funcion.

Time frame
From administration of 180MBq 18-FDG and during the 40 min brain PET scan

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nicolai Jacob Wewer Albrechtsen

Lead sponsor

University of Copenhagen

Sponsor institution

University Hospital Bispebjerg and Frederiksberg

Collaborator